322 related articles for article (PubMed ID: 12822406)
1. [Improvement of diabetes insipidus after allogeneic bone marrow transplantation in a patient with myelodysplastic syndrome].
Sato N; Takayama N; Kizaki M; Ikeda Y; Okamoto S
Rinsho Ketsueki; 2003 May; 44(5):318-22. PubMed ID: 12822406
[TBL] [Abstract][Full Text] [Related]
2. Recovery from diabetes insipidus associated with AML after a BMT conditioning regimen including busulfan.
Pagano L; Voso MT; Sica S; Leone G
Bone Marrow Transplant; 1993 Feb; 11(2):175-6. PubMed ID: 8435667
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
4. [Acute myeloid leukemia with monosomy 7 accompanied by central diabetes insipidus].
Kawano C; Muroi K; Kubota N; Takatoku M; Suzuk T; Tsunoda J; Mano H; Hatake K; Miura Y
Rinsho Ketsueki; 1997 Feb; 38(2):129-34. PubMed ID: 9059067
[TBL] [Abstract][Full Text] [Related]
5. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
[TBL] [Abstract][Full Text] [Related]
6. [Granulocyte transfusion for the treatment of prolonged pneumonia in a patient with MDS-RAEB-2 at allogeneic hematopoietic stem cell transplantation].
Morita R; Hashino S; Takahashi S; Kanamori H; Onozawa M; Kahata K; Kondo T; Imamura M; Asaka M
Rinsho Ketsueki; 2008 Feb; 49(2):89-93. PubMed ID: 18341038
[TBL] [Abstract][Full Text] [Related]
7. Translocation (7;9)(q22;q34) in therapy-related myelodysplastic syndrome after allogeneic bone marrow transplantation for acute myeloblastic leukemia.
Yamamoto K; Yakushijin K; Kawamori Y; Minagawa K; Katayama Y; Matsui T
Cancer Genet Cytogenet; 2007 Jul; 176(1):61-6. PubMed ID: 17574966
[TBL] [Abstract][Full Text] [Related]
8. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome.
Depil S; Deconinck E; Milpied N; Sutton L; Witz F; Jouet JP; Damaj G; Yakoub-Agha I;
Bone Marrow Transplant; 2004 Mar; 33(5):531-4. PubMed ID: 14716345
[TBL] [Abstract][Full Text] [Related]
9. [Diabetes insipidus as the first cause of myelodysplastic syndrome].
Krislo V; Steruská M; Krislová M; Bezdek V
Vnitr Lek; 1989 Feb; 35(2):175-8. PubMed ID: 2711626
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT: two very rare conditions in one patient.
Beck C; Humpe A; Harder S; Schmid M; Horst HA
Ann Hematol; 2005 Sep; 84(9):616-8. PubMed ID: 15782344
[TBL] [Abstract][Full Text] [Related]
11. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
12. [Eradication of adult T-cell leukemia cells and maintenance of remission by the graft-versus-leukemia effect after allogeneic bone marrow transplantation].
Ota K; Hashino S; Shimizu K; Yonezumi M; Chiba K; Kondo T; Suzuki S; Imamura M; Asaka M
Rinsho Ketsueki; 2004 Sep; 45(9):1044-7. PubMed ID: 15510833
[TBL] [Abstract][Full Text] [Related]
13. Successful bone marrow transplantation in an adult patient with reactive hemophagocytic syndrome associated with myelodysplastic syndrome.
Karasuno T; Teshima H; Hiraoka A; Nakamura H; Masaoka T
Int J Hematol; 2000 Feb; 71(2):180-3. PubMed ID: 10745629
[TBL] [Abstract][Full Text] [Related]
14. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
[TBL] [Abstract][Full Text] [Related]
15. Successful allogeneic bone marrow transplantation in a case with myelodysplastic syndrome which developed following Fanconi anemia.
Ikushima S; Hibi S; Todo S; Sawada T; Matsumoto Y; Iwami H; Tsunamoto K; Kasubuchi Y; Yabe M; Kato S
Bone Marrow Transplant; 1995 Oct; 16(4):621-4. PubMed ID: 8528182
[TBL] [Abstract][Full Text] [Related]
16. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome.
Rønnov-Jessen D; Løvgreen Nielsen P; Horn T
Bone Marrow Transplant; 1991 Nov; 8(5):413-5. PubMed ID: 1768977
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Wong R; Shahjahan M; Wang X; Thall PF; De Lima M; Khouri I; Gajewski J; Alamo J; Couriel D; Andersson BS; Donato M; Hosing C; Komanduri K; Anderlini P; Molldrem J; Ueno NT; Estey E; Ippoliti C; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2005 Feb; 11(2):108-14. PubMed ID: 15682071
[TBL] [Abstract][Full Text] [Related]
18. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
19. [Donor cell-derived acute myeloid leukemia developed shortly after allogeneic bone marrow transplantation for MDS overt leukemia].
Takahashi R; Shimazaki C; Inaba T; Nakagawa M; Yamaoka M
Rinsho Ketsueki; 2002 Oct; 43(10):963-5. PubMed ID: 12462035
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation for myelodysplastic syndrome--who? when? and which?
Luger S; Sacks N
Bone Marrow Transplant; 2002 Aug; 30(4):199-206. PubMed ID: 12203135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
